Stategic trends in the drug industry
The promise of genomics in drug discovery, which was eagerly embraced in the mid-1990s, has not yet been fulfilled. However, the influence of modern biology on drug discovery remains viable. The promise of genomics and biology should be put in context with the two central problems of drug discovery:...
Gespeichert in:
| Veröffentlicht in: | Drug discovery today 2003-05, Vol.8 (9), p.411-420 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 420 |
|---|---|
| container_issue | 9 |
| container_start_page | 411 |
| container_title | Drug discovery today |
| container_volume | 8 |
| creator | Drews, Jürgen |
| description | The promise of genomics in drug discovery, which was eagerly embraced in the mid-1990s, has not yet been fulfilled. However, the influence of modern biology on drug discovery remains viable. The promise of genomics and biology should be put in context with the two central problems of drug discovery: the search for disease-related targets, and the study of drug-protein interactions and protein-protein interactions. The first tier of the biotechnology industry has now become the most productive segment of the drug industry. It combines a high degree of innovative spirit with solid pharmaceutical professionalism. Some biotechnology firms have succeeded in addressing unmet medical needs in technologically appealing ways. In their totality, these changes will deeply alter the nature and appearance of the drug industry. |
| doi_str_mv | 10.1016/S1359-6446(03)02690-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_73219904</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>73219904</sourcerecordid><originalsourceid>FETCH-LOGICAL-p1169-ea2ff90e5f6134fd1001e892c5a5301357ab00a64383b2a9c14c0e8294bf6e483</originalsourceid><addsrcrecordid>eNqFkDtPw0AQhK8AkRD4CSAXCEFh2L0736NEES8pEkWgts72XjCyHXNnF_n3WCLQpprR6NPsahi7QLhDQHW_RpHZVEmpbkDcAlcWUnnE5v_xjJ3G-AWA3GbqhM2Qa1Aqs3N2tR7cQJu6TIZAXRWTukuGT0qqMG4mX41xCLszduxdE-l8rwv28fT4vnxJV2_Pr8uHVdojKpuS495boMwrFNJXOB0kY3mZuUzA9Ix2BYBTUhhRcGdLlCWQ4VYWXpE0YsGuf3v7sP0eKQ55W8eSmsZ1tB1jrgVHa0EeBLlVUhuDB0E0WutpiAm83INj0VKV96FuXdjlf0uJH3KEZwo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>18777659</pqid></control><display><type>article</type><title>Stategic trends in the drug industry</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Drews, Jürgen</creator><creatorcontrib>Drews, Jürgen</creatorcontrib><description>The promise of genomics in drug discovery, which was eagerly embraced in the mid-1990s, has not yet been fulfilled. However, the influence of modern biology on drug discovery remains viable. The promise of genomics and biology should be put in context with the two central problems of drug discovery: the search for disease-related targets, and the study of drug-protein interactions and protein-protein interactions. The first tier of the biotechnology industry has now become the most productive segment of the drug industry. It combines a high degree of innovative spirit with solid pharmaceutical professionalism. Some biotechnology firms have succeeded in addressing unmet medical needs in technologically appealing ways. In their totality, these changes will deeply alter the nature and appearance of the drug industry.</description><identifier>ISSN: 1359-6446</identifier><identifier>DOI: 10.1016/S1359-6446(03)02690-4</identifier><identifier>PMID: 12706659</identifier><language>eng</language><publisher>England</publisher><subject>Biotechnology - trends ; Drug Design ; Drug Industry - organization & administration ; Drug Industry - trends ; Forecasting ; Genomics ; Humans ; Marketing - economics ; Organizational Innovation ; Technology, Pharmaceutical - trends</subject><ispartof>Drug discovery today, 2003-05, Vol.8 (9), p.411-420</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12706659$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Drews, Jürgen</creatorcontrib><title>Stategic trends in the drug industry</title><title>Drug discovery today</title><addtitle>Drug Discov Today</addtitle><description>The promise of genomics in drug discovery, which was eagerly embraced in the mid-1990s, has not yet been fulfilled. However, the influence of modern biology on drug discovery remains viable. The promise of genomics and biology should be put in context with the two central problems of drug discovery: the search for disease-related targets, and the study of drug-protein interactions and protein-protein interactions. The first tier of the biotechnology industry has now become the most productive segment of the drug industry. It combines a high degree of innovative spirit with solid pharmaceutical professionalism. Some biotechnology firms have succeeded in addressing unmet medical needs in technologically appealing ways. In their totality, these changes will deeply alter the nature and appearance of the drug industry.</description><subject>Biotechnology - trends</subject><subject>Drug Design</subject><subject>Drug Industry - organization & administration</subject><subject>Drug Industry - trends</subject><subject>Forecasting</subject><subject>Genomics</subject><subject>Humans</subject><subject>Marketing - economics</subject><subject>Organizational Innovation</subject><subject>Technology, Pharmaceutical - trends</subject><issn>1359-6446</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkDtPw0AQhK8AkRD4CSAXCEFh2L0736NEES8pEkWgts72XjCyHXNnF_n3WCLQpprR6NPsahi7QLhDQHW_RpHZVEmpbkDcAlcWUnnE5v_xjJ3G-AWA3GbqhM2Qa1Aqs3N2tR7cQJu6TIZAXRWTukuGT0qqMG4mX41xCLszduxdE-l8rwv28fT4vnxJV2_Pr8uHVdojKpuS495boMwrFNJXOB0kY3mZuUzA9Ix2BYBTUhhRcGdLlCWQ4VYWXpE0YsGuf3v7sP0eKQ55W8eSmsZ1tB1jrgVHa0EeBLlVUhuDB0E0WutpiAm83INj0VKV96FuXdjlf0uJH3KEZwo</recordid><startdate>20030501</startdate><enddate>20030501</enddate><creator>Drews, Jürgen</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7TB</scope><scope>7X8</scope></search><sort><creationdate>20030501</creationdate><title>Stategic trends in the drug industry</title><author>Drews, Jürgen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p1169-ea2ff90e5f6134fd1001e892c5a5301357ab00a64383b2a9c14c0e8294bf6e483</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Biotechnology - trends</topic><topic>Drug Design</topic><topic>Drug Industry - organization & administration</topic><topic>Drug Industry - trends</topic><topic>Forecasting</topic><topic>Genomics</topic><topic>Humans</topic><topic>Marketing - economics</topic><topic>Organizational Innovation</topic><topic>Technology, Pharmaceutical - trends</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Drews, Jürgen</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Mechanical & Transportation Engineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Drug discovery today</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Drews, Jürgen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Stategic trends in the drug industry</atitle><jtitle>Drug discovery today</jtitle><addtitle>Drug Discov Today</addtitle><date>2003-05-01</date><risdate>2003</risdate><volume>8</volume><issue>9</issue><spage>411</spage><epage>420</epage><pages>411-420</pages><issn>1359-6446</issn><abstract>The promise of genomics in drug discovery, which was eagerly embraced in the mid-1990s, has not yet been fulfilled. However, the influence of modern biology on drug discovery remains viable. The promise of genomics and biology should be put in context with the two central problems of drug discovery: the search for disease-related targets, and the study of drug-protein interactions and protein-protein interactions. The first tier of the biotechnology industry has now become the most productive segment of the drug industry. It combines a high degree of innovative spirit with solid pharmaceutical professionalism. Some biotechnology firms have succeeded in addressing unmet medical needs in technologically appealing ways. In their totality, these changes will deeply alter the nature and appearance of the drug industry.</abstract><cop>England</cop><pmid>12706659</pmid><doi>10.1016/S1359-6446(03)02690-4</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1359-6446 |
| ispartof | Drug discovery today, 2003-05, Vol.8 (9), p.411-420 |
| issn | 1359-6446 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73219904 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Biotechnology - trends Drug Design Drug Industry - organization & administration Drug Industry - trends Forecasting Genomics Humans Marketing - economics Organizational Innovation Technology, Pharmaceutical - trends |
| title | Stategic trends in the drug industry |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T21%3A40%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Stategic%20trends%20in%20the%20drug%20industry&rft.jtitle=Drug%20discovery%20today&rft.au=Drews,%20J%C3%BCrgen&rft.date=2003-05-01&rft.volume=8&rft.issue=9&rft.spage=411&rft.epage=420&rft.pages=411-420&rft.issn=1359-6446&rft_id=info:doi/10.1016/S1359-6446(03)02690-4&rft_dat=%3Cproquest_pubme%3E73219904%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=18777659&rft_id=info:pmid/12706659&rfr_iscdi=true |